Dominion Diagnostics Licenses Rights to LifeGen Genetic Test Technology | GenomeWeb

NEW YORK (GenomeWeb News) – Dominion Diagnostics today said that it has licensed rights to genetic testing technology from LifeGen.

The firms are currently collaborating on a study to validate LifeGen's test, which determines a patient's Genetic Addiction Risk Score. The test is being compared in the study to the Addiction Severity Index marketed by Inflexxion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.